Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 85-93

  Mitchell, Daniel ^a   Yong, Michelle ^a   Raju, Jyothy ^a   Willemsen, Nicole ^a   Black, Matthew ^b   Trent, Amanda ^b   Tirrell, Matthew ^b   Olive, Colleen ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokines; Dendritic cells; Innate immunity; MAPK; Toll like receptors

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR;

ANIMAL CELL; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; FEMALE; HELPER CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; DENDRITIC CELLS; FEMALE; IMMUNOMODULATION; MICE; MICE, INBRED BALB C; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VACCINES, SUBUNIT;

EID: 84855743499     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14567     Document Type: Review

References (47)

1. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunological Reviews 2009; 227:221-33.
2. Geijtenbeek TBH, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009; 9:465-79.
3. Hemmi H, Akira S. TLR signaling and the function of dendritic cells. Chem Immunol Allergy 2005; 86:120-35. (Pubitemid 40905001)
4. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad of Sci USA 2004; 101:15440-5. (Pubitemid 39441560)
5. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23:6674-81. (Pubitemid 46190262)
6. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006; 176:7335-45. (Pubitemid 43849034)
7. Johnston D, Zaidi B, Bystryn JC. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 2007; 56:1133-41. (Pubitemid 46763928)
8. Chaput N, Schartz NE, andre F, Taieb J, Novault S, Bonnaventure P, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 2004; 172:2137-46. (Pubitemid 38182359)
9. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95. (Pubitemid 41057715)
10. Kawai T, Akira S. TLR signaling. Semin Immunol 2007; 19:24-32. (Pubitemid 46498752)
11. Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Akira S, et al. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 2006; 281:9049-57. (Pubitemid 43864617)
12. Schmidtke JR, Johnson AG. Regulation of the immune system by synthetic polynucleotides. I. Characteristics of adjuvant action on antibody synthesis. J Immunol 1971; 106:1191-200.
13. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675-80. (Pubitemid 32747155)
14. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95. (Pubitemid 41057715)
15. Medzhitov R, Janeway CA Jr. Innate immune induction of the adaptive immune response. Cold Spring Harb Symp Quant Biol 1999; 64:429-35. (Pubitemid 30329308)
16. O'Neill LAJ, Bowie AG. The family of five: TIR-domain- containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7:353-64. (Pubitemid 46674493)
17. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511. (Pubitemid 38931765)
18. O'Neill LAJ. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006; 18:3-9. (Pubitemid 43049641)
19. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003; 171:4984-9. (Pubitemid 37432777)
20. -/-mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J Immunol 2006; 176:5788-96.
21. Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey D, Walsh K, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008; 180:3797-806.
22. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007; 86:800-11.
23. Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1998; 1436:127-50.
24. Page TH, Smolinska M, Gillespie J, Urbaniak AM, Foxwell BMJ. Tyrosine kinases and inflammatory signalling. Curr Mol Med 2009; 9:69-85.
25. Hazeki K, Nigorikawa K, Hazeki O. Role of phosphoinositide- 3-kinase in innate immunity. Biol Pharm Bull 2007; 30:1617-23. (Pubitemid 47403233)
26. Fukao T, Tanabe M, Terauchi Y, Ota T, Matsuda S, Asano T, et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol 2002; 3:875-81.
27. Mitchell D, Olive C. Regulation of Toll-like receptor-induced chemokine production in murinedendritic cells by mitogen-activated protein kinases. Mol Immunol 2010; 47:2065-73.
28. Utsugi M, Dobashi K, Ono A, Ishizuka T, Matsuzaki S, Hisada T, et al. PI3K p110β positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role. J Immunol 2009; 182:5225-31.
29. Li H, Willingham SB, Ting JP, Re F. Cutting edge: Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008; 181:17-21.
30. Mato-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316:1628-32. (Pubitemid 46982038)
31. Redecke V, Hacker H, Datta SK, Fermin A, Pitha PM, Broide DH, et al. Cutting Edge: Activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 2004; 172:2739-43. (Pubitemid 38263655)
32. Pearce EJ, Kane C, Sun J, Taylor J, McKee AS, Cervi L. Th2 response polaraization during infection with the helminth parasite Schistosoma mansoni. Immunol Rev 2004; 201:117-26. (Pubitemid 39318447)
33. Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR, et al. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2 MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 2008; 205:79-90. (Pubitemid 351185717)
34. Allard JB, Rinaldi L, Wargo MJ, Allen G, Akira S, Uematsu S, et al. Th2 allergic immune respone to inhaled fungal antigens is modulated by TLR4-independent bacterial products. Eur J Immunol 2009; 39:776-88.
35. Jotwani R, Pulendran B, Agrawal S, Cutler CW. Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro. Eur J Immunol 2003; 33:2980-6. (Pubitemid 37428330)
36. Napolitani G, Rinaldi A, Bertoni F, Sallustro F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6:769-76. (Pubitemid 43090462)
37. Roelofs MF, Joosten LAB, Abdollahi-Roodsaz S. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4 and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis and Rheum 2005; 52:2313-22. (Pubitemid 41117415)
38. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses. Blood 2006; 108:544-50. (Pubitemid 44061354)
39. Mitchell D, Yong M, Schroder W, Black M, Tirrell M, Olive C. Dual stimulation of MyD88-dependent Toll-like receptors induces synergistically enhanced production of inflammatory cytokines in murine bone marrow-derived dendritic cells. J Infect Dis 2010; 202:318-29.
40. Dowling D, Hamilton CM, O'Neill SM. A comparative analysis of cytokine responses, cell surface marker expression and MAPKs in DCs matured with LPS compared with a panel of TLR ligands. Cytokine 2008; 41:254-62.
41. Dearman RJ, Cumberbatch M, Maxwell G, Basketter DA, Kimber I. Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. Immunology 2008; 126:475-84.
42. Dennehy KM, Ferwerda G, Faro-Trindade I, Pyz E, Willment JA, Taylor PR, et al. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol 2008; 38:500-6.
43. Wang B, Dileepan T, Briscoe S, Hyland KA, Kang J, Khoruts A, et al. Induction of TGF-β1 and TGFβ1-dependent predominant Th17 differentiation by group A streptococcal infection. Proc Natl Acad Sci USA 2010; 107:5937-42.
44. Olive C, Sun HK, Ho MF, Dyer J, Horvath A, Toth I, et al. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J Infect Dis 2006; 194:316-24. (Pubitemid 44116973)
45. Batzloff MR, Hartas J, Yeng W, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 2006; 194:325-30. (Pubitemid 44116974)
46. Chensue SW, Warmington KS, Ruth JH, Sanghi P, Lincoln P, Kunkel SL. Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (Mycobacterial) and Th2 (Schistosomal) antigen-induced granuloma formation. J Immunol 1996; 157:4602-8.
47. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000; 404:407-11. (Pubitemid 30164344)